WCLC 2023 | Challenges in development and clinical use of ADCs for lung cancer

William William, MD, The University of Texas MD Anderson Cancer Centre, Houston, TX, shares the challenges in the development and clinical use of antibody-drug conjugates (ADCs) in lung cancer. The management and mitigation of unique adverse events such as mucositis (observed in the use of datopotamab deruxtecan), pneumonitis and bone marrow toxicity has been a recent challenge in ADC treatment. Difficulties have also appeared in identifying biomarkers, ADC targets, and the appropriate lung cancer populations. The activity of ADCs in the central nervous system is also unknown, however preliminary results suggest that patritumab deruxtecan may have an effect. Dr William reports that the mechanism of action of some ADCs, the kinetics of their receptors, and the tumour resistance mechanisms against the drugs are still being researched.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.